Treatments for renal cell carcinoma, while promising, are still limited by toxicity and cost. In the hopes of finding a novel compound or combination, we developed a plasmid containing the genes for interleukin-2 (IL-2) and soluble vascular endothelial growth factor receptor 2 (msFlk1). The plasmid, p2CMVIL2/msFlk1, demonstrated similar in vitro transgene expression of IL-2 or msFlk1 compared to their single-agent counterparts. Subcutaneous tumor growth was significantly inhibited in the p2CMVIL2/msFlk1 group when delivered locally by the non-viral water soluble polymer, WSLP and exhibited a 50% increase in survival over glucose and single-agent controls. In vivo experimentation demonstrated that WSLP/msFlk1 decreased microvessel density in pCMVmsFlk1 and p2CMVIL2/msFlk1 treated groups. Furthermore, tumor-infiltrating lymphocytes expressing CD45RO and CD68 were increased within the tumor microenvironment upon p2CMVIL2/msFlk1 treatment. To determine the effects of p2CMVIL2/msFlk1 in an experimental RENCA lung metastases model, therapeutic DNA was delivered systemically following complexation with the angiogenic endothelial-targeting polymer PEI-g-PEG-RGD. The p2CMVIL2/msFlk1 treatment significantly reduced metastases by 56% over single-agent therapy and increased survival proportions by 50% over all groups. Our work clearly demonstrates that non-viral delivery of p2CMVIL2/msFlk1 can inhibit RENCA growth in a synergistic manner and may represent a new treatment for renal carcinoma.
Introduction
Renal cell carcinoma (RCC) is characterized by a lack of early warning signs, diverse clinical manifestations and resistance to conventional radiation and chemotherapies. Indeed, this illustrates the complexities faced in providing suitable treatments for RCC. 1 The 5-year survival rates of renal cell carcinoma initially reported in 1969 have remained virtually unchanged except for stage I having a modest increase in survival during early detection. 2, 3 Renal cell carcinoma continues to be a major health issue, and predictions indicate the disease will become increasingly difficult over time.
Immunotherapy using high bolus dose interleukin-2 (IL-2) has been a current treatment option as it exhibits a direct anti-proliferative effect upon diagnosed renal cell carcinoma. However, this treatment is associated with high morbidity and cost. 4, 5 Recent advances in antiangiogenic research have led to new compounds for use in renal cell carcinoma; whereas a large proportion of clinical examples overexpress vascular endothelial growth factor VEGF, this overexpression does not appear to correlate with survival. 6 Unfortunately, studies have demonstrated that without continuous infusion these angiogenic inhibitors rarely achieve optimal efficacy and help to explain the little or limited success of these early agents. 7, 8 Therefore, it is clear that a new therapy is needed to improve survival and the therapeutic index.
The use of gene therapy is a well-documented delivery method that can overcome the short half-life of in-situ proteins and reduce toxicity associated with high bolus dosing. Leuvectin s is a liposomal delivery agent that has accomplished phase I and II clinical trials for the treatment of renal cell carcinoma to deliver IL-2 pDNA with good overall response and tolerability. 9 The use of non-viral vectors has increased in recent years due to advances in the field and the absence of genomic integration that has recently plagued retroviral delivery. 10 Our hypothesis is that plasmid delivery of IL-2 and the soluble VEGF receptor (sFlk-1) would inhibit tumor growth while initiating an immunomodulatory response. We demonstrate here that the delivery of the plasmid pCMVIL2/msFlk1 by novel non-viral gene delivery agents not only decreases the primary tumor volume and vessel density, but also significantly inhibit metastatic growth and improve survival over the singleagents alone in a mouse model of renal cell carcinoma. To our knowledge, this is the first such gene combination in use for cancer gene therapy.
Results and discussion
IL-2 and msFlk-1 cDNA was placed downstream of the CMV promoter in the pCI plasmid. By placing the msFlk1 expression cassette upstream of the IL-2 cassette within the pCMVIL2 plasmid, the p2CMVIL2/msFlk1 plasmid was created ( Figure 1a ). All generated plasmids were sequenced and confirmed for verification. Transgene expression of the constructed plasmids was accomplished by RT-PCR. RENCA cells were transfected with either 2 mg of pCMVhIL2, pCMVmsFlk-1 or p2CMVIL2/msFlk1 alone or complexed with WSLP at 15:1 N/P ratio. Significant elevation of hIL-2 mRNA levels versus non-transfected and DNA alone controls was only demonstrated for WSLP/pCMVIL2 and WSLP/p2CMVIL2/msFlk1 complexes (Figure 1b) .
Dual expression plasmids have been previously utilized by this lab and shown to be better than vectors utilizing internal ribosome entry sites. 11 To demonstrate quickly activity and efficacy, we created the p2CMVIL2/ msFlk1 plasmid vector instead of a fusion protein.
Validation of the concept exists in similar studies demonstrating synergistic effects using immune-modulatory cytokines and anti-angiogenic agents. [12] [13] [14] [15] These combinations demonstrate enhanced efficacy with reduced toxicity as the levels of both components are reduced and these both factors are required for an effective therapy in renal cell carcinoma.
Synergistic role of p2CMVIL2/msFlk1 in reduction of tumor burden
The RENCA model of renal cell carcinoma was used to generate a subcutaneous and a metastatic model for comparison testing of the combination plasmid with its single expression controls. A 100 ml of WSLP/pDNA complexes (50 mg) were injected peri-tumorally on days 7 and 14, once the average tumor volume of the groups reached 50 mm 3 . Two days following the second injection, 50% of the tumors were not palpable in the p2CMVIL2/msFlk1 group (see Figure 2a ). Injections were halted and half of each group was assessed for survival ( Figure 2b ). Median survival time of the p2CMVIL22/msFlk1 group was increased by an average of 73% compared to all other groups. Interestingly, the RENCA tumor growth was not as susceptible to the pCMVIL2 delivery as was hoped. Sequencing and ELISA confirmed the expression of hIL2 from in vitro transfected cells (data not shown) to remove doubt from the expression vector construct. Closer examination of the pCMVIL2 group showed that 25% of animals responded to the treatment by retarding tumor growth whereas this was lower in the pCMVmsFlk1 group. This suggests that the expression levels of hIL-2 needs to be increased to demonstrate a greater efficacy. Unfortunately, this may lead to toxicity. The hIL-2 levels expressed by the pCMVIL2 and p2CMVIL2msFlk1 plasmids are similar in in vitro testing, so the combination of IL-2 and msFlk1 appears to be responsible for the efficacy seen. Previous work using a similar expression construct but expressing IL-4 and IL-10 demonstrated that a cotransfection of two separate plasmids produces less protein and has reduced efficacy in a diabetic model than its bicistronic counterpart. 16 Cationic polymers exhibit aggregation of pDNA/ complexes with increasing concentrations that limit the amount of DNA to be injected, so volumes have to be increased to allow for proper molar concentrations to be observed and was not examined.
The second most common site of renal cell carcinoma metastasis is the lung. 16 To evaluate the effects of p2CMVIL2/msFlk1 on experimental lung metastases, we injected 40 mg of therapeutic pDNA complexed to the systemic angiogenic endothelial targeting polymer, PEIg-PEG-RGD. This polymer has been used previously to effectively deliver soluble VEGFR1 (sFlt1) to an ectopic colon carcinoma model and inhibit its growth. 17 We calculated the number of surface lung metastases by staining the excised lungs with a 5% solution of Methylene Blue in PBS for 5 min. The metastases can be distinguished from normal tissue by a slight blue color due to the difference in rate of stain diffusion into cancerous versus normal lung tissue. Single therapies reduced the number of lung metastases over controls, while the p2CMVIL2/msFlk1 treated groups saw a Non-viral delivery of interleukin-2 and soluble Flk-1 JW Yockman et al significant reduction (Po0.001) in metastases by over 50% (Figure 2c ). However, this significance did not extend towards survival, though there was an increase in survival by more than 40% (Figure 2d ). WSLP and PEI-g-PEG-RGD polymers to conjugate and deliver pDNA were used based on their unique characteristics and properties. WSLP was designed for local delivery only and biodistribution studies following intravenous injection revealed similar levels of polymer and pDNA in the lung as bPEI25k (data not published). However, PEI-g-PEG-RGD was designed explicitly for systemic delivery and for targeting angiogenic endothelium. 18, 19 The biodistribution profile of the polymer demonstrates enhanced targeting of the polymer/pDNA complexes to tumors over PEI-g-PEG conjugates and performs significantly better in tumor growth inhibition studies. 19 p2CMVIL2/msFlk1 decreases vessel density and enhances TIL numbers Anti-angiogenic effects of sFlk1 have been demonstrated in numerous other in vitro and in vivo models in which tumor growth inhibition of more than 80% was seen in vessel formation compared to controls. 20 ,21 Therefore, we tested for the ability of the plasmids to inhibit vessel formation in vivo by staining for CD31 (Figure 3 ). Controls and pCMVIL2 treated tumors stained heavily for CD31 while the pCMVmsFlk1 and p2CMVIL2/ msFlk1 staining was much less intense. The tumor vessel density was significantly reduced for pCMVmsFlk1 and p2CMVIL2/msFlk1 treated groups when compared to the glucose only control and pCMVIL2 groups, when analyzed (Po0.001 and Po0.05, respectively). However, Figure 2 clearly demonstrates that polymeric gene delivery for msFlk1 expression is, by itself, not enough to significantly alter RENCA tumor growth and must be combined with IL2 expression. The polymeric delivery of soluble Flt-1 (sFlt1) using PEI-g-PEG-RGD is sufficient to inhibit CT-26 tumor growth most likely by binding to VEGF. The sFlk1 also binds to the same VEGF splice variants, but the activation of the VEGF receptor-2 is sufficient and necessary to mediate VEGF-mediated angiogenesis. 22 The plasmids are based on the same backbone and expression should be similar. Therefore, it is possible that there is a difference in VEGF or other angiogenic factor expression between the two cell lines that sFlk-1 and most likely sFlt-1 cannot effectively control tumor growth using this expression system. However, the dual expression of hIL-2 and msFlk-1 is able to inhibit and/or regress tumor growth and lung metastasis. Cells activated in the presence of hIL-2 must assist in the inhibition/regression of tumor growth created by sFlk1 expression.
The mechanism of action for IL2 effectiveness is through the activation of lymphoid cells rather than inhibition of tumor growth. 23, 24 Instead of monitoring the individual expansion of CD4/CD8/NK cells, we examined the number of activated lymphocytes, specifically CD45RO at the tumor site to confirm the effects of IL2 activity (Figure 4 ). CD45RO-positive cells increased in pCMVIL2 and p2CMVIL2/msFlk1 treated animals over controls and pCMVmsFlk1 groups (Figure 4a-d) .
Once again a discrepancy exists in that similar staining exists for activated lymphocyte infiltration for both pCMVIL2 and p2CMVIL2/msFlk1 treated tumors, but only one treatment shows efficacy. Complete conversion of naïve T-cells expressing CD45RA into CD45RO cells is both time and concentration dependent and may not represent the active T-cell population when measured at Figure 2 Combination plasmid p2CMVIL2/msFlk1 has a significant effect on tumor inhibition and survival. RENCA tumors were injected locally with 25 mg of WSLP/pDNA and animals were monitored for tumor growth (a) and survival (b). Animals treated with p2CMVIL2/ msFlk1 had a significant decrease in tumor volume compared to pCMVIL2 and pCMVmsFlk1 (Po0.05) and controls (Po0.001), n ¼ 10. This significance is also exhibited when delivered systemically by PEI-g-PEG-RGD on reduction of lung metastases Po0.001 (c) and survival (d).
Non-viral delivery of interleukin-2 and soluble Flk-1 JW Yockman et al such an early stage following IL-2 expression (14 days). 25 The CD45RO antigen is also expressed on 40% of unactivated T cells, monocytes, macrophages and granulocytes. 26, 27 What little T-cell activation that may have occurred may be over-ridden by the overwhelming growth of the cells or immune evasion. 28, 29 Expression of msFlk1 or its hypoxic effects may serve to alter the expression of these evasive mechanisms (due to growth inhibition) and in combination with IL-2 assist in activation of the immune response. Further investigations are warranted to identify specific populations of cells responsible for this discrepancy.
Conclusion
The use of non-viral gene delivery agents for therapeutic applications are becoming a prominent focus in the field. The initial goal of non-viral gene delivery was to meet or surpass viral gene delivery vehicles. Even though the transfection efficiency has not been met in all counts, the efficacy reached by non-viral agents is noteworthy. Interestingly enough, the single-agents delivered in this report were not enough to inhibit RENCA tumor growth although several reports using either agent delivered by a viral vector in other tumor settings were sufficient. This lack of tumor growth inhibition does not imply an ineffectiveness of the polymers ability to deliver therapeutic genes, but more likely the tumors particular response to each agent itself. In this regard, we generated a plasmid (p2CMVIL2/msFlk1) that delivered both agents simultaneously, which significantly enhanced tumor inhibition and metastases growth. A longer treatment schedule would be needed to determine if the p2CMVIL2/msFlk1 could generate a memory T-cell response and challenge subsequent tumors; however, our studies indicate that this is entirely possible. Non-viral delivery of interleukin-2 and soluble Flk-1 JW Yockman et al
Materials and methods

Plasmid construction
The pCMVIL-2 and pCMVmsFlk1 plasmids were generated by converting mRNA isolated from the Jurkat cell line and 16.5d fetal mouse into cDNA using Oligo dT (Invitrogen, Burlingame CA, USA). The following primers: IL2 forward 5 0 -gtgcagaattcatctacaggatgcaac-3 0 ; IL2 reverse 5 0 -cacaacgtcgactaagtcagtgttgag-3 0 and msFlk1 forward 5 0 -gacgaattcatggagagcaaggcgctgcta-3 0 ; msFlk1 reverse 5 0 -ctctagaccaccaaagatttcatcccac-3 0 were then used for PCR, isolated by gel electrophoresis and ligated into the pCI plasmid (Promega, Madison WI, USA) at the EcoRI and SalI sites. The p2CMVIL2/msFlk1 plasmid was generated by digesting the msFlk1 cassette from the pCMVmsFlk1 plasmid using BglII and BamHI restriction endonucleases and ligating it into the BglII site of the pCMVIL2 plasmid. Vector software used was ApE v1.11 (M Wayne Davis, University of Utah, UT, USA).
Synthesis of WSLP
The synthesis of WSLP was described previously. 11 Briefly, WSLP was synthesized by stirring 3 g branched PEI (molecular weight 1800) on ice in a mixture of 10 ml anhydrous methylene chloride and 100 ml triethylamine for 30 min. One gram of cholesteryl chloroformate was dissolved in 5 ml anhydrous ice-cold methylene chloride and then slowly added it to the PEI solution for 30 min. The mixture was stirred for 12 h on ice and the resulting product was dried on a rotary evaporator. The powder was dissolved in 50 ml of 0.1 N HCl and then filtered through a glass microfiber filter. Non-reacted cholesteryl chloroformate was removed by washing the aqueous solution three times with 100 ml methylene chloride then was filtered through a glass microfiber filter. The resultant product was concentrated by solvent evaporation, precipitated with excess acetone and dried under a vacuum. The powder was dissolved in water and precipitated three times with acetone. After washing with methanol, the product was washed three times with diethyl ether. The white powder product was characterized using matrix-assisted laser desorption-time-of-flight (MALDI-TOF) mass spectrophotometry (Perspective Voyager-DE STR, PE Applied Biosystem Co., Framingham, MA, USA) with trans-4-hydroxy-3-methoxycinnamic acid as matrix and 400 MHz 1 H NMR (Varian Inc., Palo Alto, CA, USA).
Synthesis of PEI-g-PEG-RGD
The synthesis of PEI-g-PEG-RGD conjugate consists of two reaction steps as described previously. 18 Briefly, RGD peptide was dissolved in anhydrous DMF containing 4 M excess of TEA. NHS-PEG-VS was also dissolved in anhydrous DMF and immediately mixed with the peptide solution. After a 2 h incubation at room temperature, cold anhydrous ether was added and the RGD-PEG-VS conjugate and free peptide was precipitated out. Following drying, the precipitate was dissolved in sodium carbonate buffer (pH 9.0) and filtered through a 0.22-mm filter to remove free peptide. The RGD-PEG-VS conjugates were mixed with PEI solution in sodium carbonate buffer (pH 9.0) and stirred overnight at room temperature. PEI-g-PEG-RGD was characterized by 1H-NMR (Varian, Palo Alto, CA, USA) at the reaction and conjugation step.
In vivo experimentation
Five-week-old female Balb/c mice were purchased from Charles River and maintained on ad libitum rodent feed and water at room temperature, 40% humidity. Balb/c mice were injected subcutaneously in the right flank with 1 Â 10 6 RENCA cells and tumor size was measured after 10 days. RENCA bearing animals were injected weekly, with either 5% glucose solution, 25 mg of pCMVIL2, pCMVmsFlk1 or p2CMVIL2/msFlk1 complexed with WSLP (15:1 N/P ratio) in 50 ml. The mice were sorted based on tumor size to normalize the groups. Tumors were measured every 3-4 days using a vernier caliper and the volume calculated using the formula V ¼ 0.5ab 2 where a is the longest length and b the shortest length.
The experimental lung metastases model required 1 Â 10 5 RENCA injected intravenously. Ten days following injection, the mice were injected with either 5% glucose solution, 40 mg of pCMVIL2, pCMVmsFlk1 or p2CMVIL2/msFlk1 complexed with PEI-g-PEG-RGD (5:1 N/P ratio) in 200 ml. Animals were weighed weekly and evaluated according to IACUC standards. Following the death of the first control, five animals from each group were killed and the lungs were excised. The number of surface lung metastases was calculated by staining the lungs with a 5% solution of Methylene Blue in PBS for 5 min. The metastases can be distinguished from normal tissue by a slight blue color due to the difference in rate of stain diffusion into cancerous versus normal lung tissue.
RT-PCR
RENCA cells were plated at 1 Â 10 5 cells/well in a 6-well plate. Cells were transfected with 2 mg of pCMVIL2, pCMVmsFlk1 or p2CMVIL2/msFlk1 as described above. Cells were collected at 48 h and total RNA was isolated using the RNEasy kit (Qiagen, Valencia, CA, USA) and quantified by 260/280 nm measurement using the NanoDrop ND-1000 (Nanodrop Technologies, Wilmington, DE, USA). Five hundred nanograms of total 
Immunohistochemistry and vessel density assay
Tumor samples were flash-frozen upon excision in liquid nitrogen and embedded in OCT compound before sectioning. The blocking agent CD16/32 (BD Biosciences, San Jose, CA, USA) was used at 1:250. Rat anti-mouse CD31 (BD Bioscience) was used at 1:50 followed by a biotinylated rabbit anti-rat IgG (H+L) (Vector Labs, Burlingame, CA, USA) at 1:500. HRP-Streptavidin was used for visualization and hematoxylin as a counterstain. The microvessel density was calculated as the mean number of stained vessels within three random microscopic fields viewed at Â 200 on each slide. These microscopic fields are 0.391 mm 2 . Sections for CD45RO/CD68 staining were placed in a microwave at half-power for 15 min in citrate buffer (pH 6.0). Primary antibodies were placed on the sections at 1:3000 and 1:2500, respectively for 30 min. The secondary antibody was HRP anti-mouse Fab 0 (Dako, Carpinteria, CA, USA) at 1:300 dilution for 12 min.
Statistical analysis
Data were analyzed using Prism 4.0 (Graphpad Software Inc., San Diego, CA, USA). All tests were performed using one-way ANOVA with Tukey's post-hoc test. Survival data were calculated using a Kaplan-Meier survival analysis.
